Multipotent Mesenchymal Stromal Cells: Clinical Applications and Cancer Modeling

  • René RodríguezEmail author
  • Javier García-Castro
  • Cesar Trigueros
  • Mariano García Arranz
  • Pablo Menéndez
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 741)


The recognition of the therapeutic potential of Multipotent Mesenchymal Stromal Cells (MSCs) is one of the most exciting recent advances in cell therapy. In just ten years, since the description of the multilineage potential of MSCs by Pittenger et al in 1999 until now, MSCs are being used in more than 150 clinical trials as therapeutic agents. The potential of these cells for cell-based therapies relies on several key properties: (1) their capacity to differentiate into several cell lineages; (2) their lack of immunogenicity and their immunomodulatory properties; (3) their ex vivo expansion potential; (4) their ability to secrete soluble factors which regulate crucial biological functions such as proliferation and differentiation over a broad spectrum of target cells; and (5) their ability to home to damaged tissues and tumor sites. Based on these properties MSCs are being exploited worldwide for a wide range of potential clinical applications including cell replacement strategies, treatment of graft-versus-host disease, autoimmune diseases and rejection after solid organ transplantation as well as their use as vehicles to deliver anti-cancer therapies. Importantly, the low inherent immunogenicity of MSCs means that they could be used not only for autologous but also for allogeneic cell therapies. In addition, increasing evidence has revealed a complex relationship between MSCs and cancer. Thus, solid evidence has placed MSCs transformed with specific mutations as the most likely cell of origin for certain sarcomas, and MSCs have been reported to both, inhibit or promote tumor growth depending on yet undefined conditions. Here we will thoroughly discuss the different potential clinical applications of MSC as well as the role of MSCs on sarcomagenesis and the control of tumor growth.


Stem Cell Mesenchymal Stem Cell Mesenchymal Stromal Cell Human Mesenchymal Stem Cell Bone Marrow Mesenchymal Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Friedenstein AJ, Piatetzky S, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16:381–390.PubMedGoogle Scholar
  2. 2.
    Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy 2005; 7:393–395.PubMedGoogle Scholar
  3. 3.
    Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006; 8:315–317.PubMedGoogle Scholar
  4. 4.
    da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119:2204–2213.PubMedGoogle Scholar
  5. 5.
    Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24:1294–1301.PubMedGoogle Scholar
  6. 7.
    Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991; 78:55–62.PubMedGoogle Scholar
  7. 8.
    Quirici N, Soligo D, Bossolasco P et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002; 30:783–791.PubMedGoogle Scholar
  8. 9.
    Anjos-Afonso F, Bonnet D. Nonhematopoietic/endothelial SSEA-1??cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood 2007; 109:1298–1306.PubMedGoogle Scholar
  9. 10.
    Gang EJ, Bosnakovski D, Figueiredo CA et al. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007; 109:1743–1751.PubMedGoogle Scholar
  10. 11.
    Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131:324–336.PubMedGoogle Scholar
  11. 12.
    Martinez C, Hofmann TJ, Marino R et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007; 109:4245–4248.PubMedGoogle Scholar
  12. 13.
    Dezawa M, Kanno H, Hoshino M et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 2004; 113:1701–1710.PubMedGoogle Scholar
  13. 14.
    Jackson L, Jones DR, Scotting P et al. Adult mesenchymal stem cells: differentiation potential and therapeutic applications. J Postgrad Med 2007; 53:121–127.PubMedGoogle Scholar
  14. 15.
    Luk JM, Wang PP, Lee CK et al. Hepatic potential of bone marrow stromal cells: development of in vitro coculture and intra-portal transplantation models. J Immunol Methods 2005; 305:39–47.PubMedGoogle Scholar
  15. 16.
    Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143–147.PubMedGoogle Scholar
  16. 17.
    Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3:301–313.PubMedGoogle Scholar
  17. 18.
    da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26:2287–2299.PubMedGoogle Scholar
  18. 19.
    Awaya N, Rupert K, Bryant E et al. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 2002; 30:937–942.PubMedGoogle Scholar
  19. 20.
    Koc ON, Peters C, Aubourg P et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999; 27:1675–1681.PubMedGoogle Scholar
  20. 21.
    Rieger K, Marinets O, Fietz T et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol 2005; 33:605–611.PubMedGoogle Scholar
  21. 22.
    Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21:1733–1738.PubMedGoogle Scholar
  22. 23.
    Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211:27–35.PubMedGoogle Scholar
  23. 24.
    Devine SM, Bartholomew AM, Mahmud N et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29:244–255.PubMedGoogle Scholar
  24. 25.
    Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002; 99:8932–8937.PubMedGoogle Scholar
  25. 26.
    Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439–1441.PubMedGoogle Scholar
  26. 27.
    Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67:9142–9149.PubMedGoogle Scholar
  27. 28.
    Rosland GV, Svendsen A, Torsvik A et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009; 69:5331–5339.PubMedGoogle Scholar
  28. 29.
    Garcia-Castro J, Trigueros C, Madrenas J et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008; 12:2552–2565.PubMedGoogle Scholar
  29. 30.
    Li YP, Paczesny S, Lauret E et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008; 180:1598–1608.PubMedGoogle Scholar
  30. 31.
    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815–1822.PubMedGoogle Scholar
  31. 32.
    Zhang B, Liu R, Shi D et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113:46–57.PubMedGoogle Scholar
  32. 33.
    Fernandez-Miguel G, Bovy T. Production of cell-based medicines for somatic cell therapy. In: Garcia-Olmo D, Garcia-Verdugo JM, Alemany J, Gutierrez-Funetes JA, eds. Cell Therapy. Madrid: McGraw-Hill/Interamericana de España; 2008:33–41.Google Scholar
  33. 34.
    Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109:4119–4126.PubMedGoogle Scholar
  34. 35.
    Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667–674.PubMedGoogle Scholar
  35. 36.
    Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756–762.PubMedGoogle Scholar
  36. 37.
    Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81:1390–1397.PubMedGoogle Scholar
  37. 38.
    Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009; 11:503–515.PubMedGoogle Scholar
  38. 39.
    Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61:219–227.PubMedGoogle Scholar
  39. 40.
    Stagg J, Pommey S, Eliopoulos N et al. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107:2570–2577.PubMedGoogle Scholar
  40. 41.
    Abarbanell AM, Wang Y, Herrmann JL et al. Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol; 298:H1529–H1536.Google Scholar
  41. 42.
    Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 2009; 27:966–967.PubMedGoogle Scholar
  42. 43.
    Boulton AJ, Vileikyte L, Ragnarson-Tennvall G et al. The global burden of diabetic foot disease. Lancet 2005; 366:1719–1724.PubMedGoogle Scholar
  43. 44.
    Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341:738–746.PubMedGoogle Scholar
  44. 45.
    Falanga V, Iwamoto S, Chartier M et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007; 13:1299–1312.PubMedGoogle Scholar
  45. 46.
    McFarlin K, Gao X, Liu YB et al. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen 2006; 14:471–478.PubMedGoogle Scholar
  46. 47.
    Wu Y, Chen L, Scott PG et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007; 25:2648–2659.PubMedGoogle Scholar
  47. 48.
    Majd H, Wipff PJ, Buscemi L et al. A novel method of dynamic culture surface expansion improves mesenchymal stem cell proliferation and phenotype. Stem Cells 2009; 27:200–209.PubMedGoogle Scholar
  48. 50.
    Lataillade JJ, Doucet C, Bey E et al. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen Med 2007; 2:785–794.PubMedGoogle Scholar
  49. 51.
    Garcia-Olmo D, Herreros D, Pascual I et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52:79–86.PubMedGoogle Scholar
  50. 52.
    Kon E, Muraglia A, Corsi A et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res 2000; 49:328–337.PubMedGoogle Scholar
  51. 53.
    Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5:309–313.PubMedGoogle Scholar
  52. 54.
    Marcacci M, Kon E, Moukhachev V et al. Stem cells associated with macroporous bioceramics for long bone repair: 6-to 7-year outcome of a pilot clinical study. Tissue Eng 2007; 13:947–955.PubMedGoogle Scholar
  53. 55.
    Quarto R, Mastrogiacomo M, Cancedda R et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344:385–386.PubMedGoogle Scholar
  54. 56.
    Gangji V, Hauzeur JP. Treating osteonecrosis with autologous bone marrow cells. Skeletal Radiol 2010; 39:209–211.PubMedGoogle Scholar
  55. 57.
    Kurth T, Hedbom E, Shintani N et al. Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthritis Cartilage 2007; 15:1178–1189.PubMedGoogle Scholar
  56. 58.
    Fuster V, Sanz J. Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research. Nat Clin Pract Cardiovasc Med 2007; 4 Suppl 1:S1–S8.PubMedGoogle Scholar
  57. 59.
    Mazhari R, Hare JM. Advances in cell-based therapy for structural heart disease. Prog Cardiovasc Dis 2007; 49:387–395.PubMedGoogle Scholar
  58. 60.
    Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008; 453:322–329.PubMedGoogle Scholar
  59. 61.
    Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451:937–942.PubMedGoogle Scholar
  60. 62.
    Togel F, Westenfelder C. Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 2007; 236:3321–3331.PubMedGoogle Scholar
  61. 63.
    Stagg J. Mesenchymal stem cells in cancer. Stem Cell Rev 2008; 4:119–124.PubMedGoogle Scholar
  62. 64.
    Ritter E, Perry A, Yu J et al. Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann Surg 2008; 247:310–314.PubMedGoogle Scholar
  63. 65.
    Dwyer RM, Potter-Beirne SM, Harrington KA et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007; 13:5020–5027.PubMedGoogle Scholar
  64. 66.
    Xu WT, Bian ZY, Fan QM et al. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett 2009; 281:32–41.PubMedGoogle Scholar
  65. 67.
    Stoff-Khalili MA, Rivera AA, Mathis JM et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007; 105:157–167.PubMedGoogle Scholar
  66. 68.
    Komarova S, Kawakami Y, Stoff-Khalili MA et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5:755–766.PubMedGoogle Scholar
  67. 69.
    Sonabend AM, Ulasov IV, Tyler MA et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008; 26:831–841.PubMedGoogle Scholar
  68. 70.
    Yong RL, Shinojima N, Fueyo J et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009; 69:8932–8940.PubMedGoogle Scholar
  69. 71.
    Garcia-Castro J, Alemany R, Cascallo M et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther 2010.Google Scholar
  70. 72.
    Loebinger MR, Janes SM. Stem cells as vectors for antitumour therapy. Thorax 2010; 65:362–369.PubMedGoogle Scholar
  71. 73.
    Grisendi G, Bussolari R, Cafarelli L et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010; 70:3718–3729.PubMedGoogle Scholar
  72. 74.
    Kim SM, Lim JY, Park SI et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68:9614–9623.PubMedGoogle Scholar
  73. 75.
    Loebinger MR, Eddaoudi A, Davies D et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69:4134–4142.PubMedGoogle Scholar
  74. 76.
    Menon LG, Kelly K, Yang HW et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009; 27:2320–2330.PubMedGoogle Scholar
  75. 77.
    Mohr A, Lyons M, Deedigan L et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008.Google Scholar
  76. 78.
    Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009; 106:4822–4827.PubMedGoogle Scholar
  77. 79.
    Uchibori R, Okada T, Ito T et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009; 11:373–381.PubMedGoogle Scholar
  78. 80.
    Zischek C, Niess H, Ischenko I et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009; 250:747–753.PubMedGoogle Scholar
  79. 81.
    Cavarretta IT, Altanerova V, Matuskova M et al. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 2010; 18:223–231.PubMedGoogle Scholar
  80. 82.
    Kucerova L, Altanerova V, Matuskova M et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67:6304–6313.PubMedGoogle Scholar
  81. 83.
    Vermeulen L, Sprick MR, Kemper K et al. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008.Google Scholar
  82. 84.
    Castillero-Trejo Y, Eliazer S et al. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005; 65:8698–8705.PubMedGoogle Scholar
  83. 85.
    Riggi N, Cironi L, Provero P et al. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005; 65:11459–11468.PubMedGoogle Scholar
  84. 86.
    Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006; 66:7016–7023.PubMedGoogle Scholar
  85. 87.
    Charytonowicz E, Cordon-Cardo C, Matushansky I et al. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett 2009; 279:126–136.PubMedGoogle Scholar
  86. 88.
    Ren YX, Finckenstein FG, Abdueva DA et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008; 68:6587–6597.PubMedGoogle Scholar
  87. 89.
    Suva ML, Riggi N, Stehle JC et al. Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res 2009; 69:1776–1781.PubMedGoogle Scholar
  88. 90.
    Riggi N, Suva ML, Suva D et al. EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68:2176–2185.PubMedGoogle Scholar
  89. 91.
    Tirode F, Laud-Duval K, Prieur A et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11:421–429.PubMedGoogle Scholar
  90. 92.
    Matushansky I, Hernando E, Socci ND et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008; 172:1069–1080.PubMedGoogle Scholar
  91. 93.
    De Boer J, Wang HJ, Van Blitterswijk C. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng 2004; 10:393–401.PubMedGoogle Scholar
  92. 94.
    Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19:150–158.PubMedGoogle Scholar
  93. 95.
    Neth P, Ciccarella M, Egea V et al. Wnt signaling regulates the invasion capacity of human mesenchymal stem cells. Stem Cells 2006; 24:1892–1903.PubMedGoogle Scholar
  94. 96.
    Neth P, Ries C, Karow M et al. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 2007; 3:18–29.PubMedGoogle Scholar
  95. 97.
    Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117:3248–3257.PubMedGoogle Scholar
  96. 98.
    Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009; 101:2064.PubMedGoogle Scholar
  97. 99.
    Miura M, Miura Y, Padilla-Nash HM et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006; 24:1095–1103.PubMedGoogle Scholar
  98. 100.
    Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25:371–379.PubMedGoogle Scholar
  99. 101.
    Wang Y, Huso DL, Harrington J et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7:509–519.PubMedGoogle Scholar
  100. 102.
    Cruet-Hennequart S, Prendergast AM, Barry FP et al. Human Mesenchymal Stem Cells (hMSCs) as targets of DNA damaging agents in cancer therapy. Curr Cancer Drug Targets 2010.Google Scholar
  101. 103.
    Mueller LP, Luetzkendorf J, Mueller T et al. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006; 24:2753–2765.PubMedGoogle Scholar
  102. 104.
    Berman SD, Calo E, Landman AS et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A 2008; 105:11851–11856.PubMedGoogle Scholar
  103. 105.
    Li H, Fan X, Kovi RC et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res 2007; 67:10889–10898.PubMedGoogle Scholar
  104. 106.
    Rodriguez R, Rubio R, Masip M et al. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 2009; 11:397–407.PubMedGoogle Scholar
  105. 107.
    Rubio R, Garcia-Castro J, Gutierrez-Aranda I et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010.Google Scholar
  106. 108.
    Ban J, Bennani-Baiti IM, Kauer M et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing’s sarcoma. Cancer Res 2008; 68:7100–7109.PubMedGoogle Scholar
  107. 109.
    Cordon-Cardo C, Latres E, Drobnjak M et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54:794–799.PubMedGoogle Scholar
  108. 110.
    Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3:685–694.PubMedGoogle Scholar
  109. 111.
    Oda Y, Yamamoto H, Takahira T et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 2005; 207:410–421.PubMedGoogle Scholar
  110. 112.
    Lin PP, Pandey MK, Jin F et al. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009; 30:1789–1795.PubMedGoogle Scholar
  111. 113.
    Shima Y, Okamoto T, Aoyama T et al. In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12. Biochem Biophys Res Commun 2007; 353:60–66.PubMedGoogle Scholar
  112. 114.
    Serakinci N, Guldberg P, Burns JS et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004; 23:5095–5098.PubMedGoogle Scholar
  113. 115.
    Choumerianou DM, Dimitriou H, Perdikogianni C et al. Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif 2008; 41:909–922.PubMedGoogle Scholar
  114. 116.
    Gou S, Wang C, Liu T et al. Spontaneous differentiation of murine bone marrow-derived mesenchymal stem cells into adipocytes without malignant transformation after long-term culture. Cells Tissues Organs 2010; 191:185–192.PubMedGoogle Scholar
  115. 117.
    Tarte K, Gaillard J, Lataillade JJ et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115:1549–1553.PubMedGoogle Scholar
  116. 118.
    Garcia S, Martin MC, de la Fuente R et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010.Google Scholar
  117. 119.
    Ramos CA, Asgari Z, Liu E et al. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 2010.Google Scholar
  118. 120.
    Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26:1387–1394.PubMedGoogle Scholar
  119. 121.
    Houghton J, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306:1568–1571.PubMedGoogle Scholar
  120. 122.
    Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557–563.PubMedGoogle Scholar
  121. 123.
    Molloy AP, Martin FT, Dwyer RM et al. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009; 124:326–332.PubMedGoogle Scholar
  122. 124.
    Patel SA, Meyer JR, Greco SJ et al. Mesenchymal stem cells protect breast cancer cells through regulatory T-cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010.Google Scholar
  123. 125.
    Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res 2009; 69:1255–1258.PubMedGoogle Scholar
  124. 126.
    Bueno C, Lopes LF, Menendez P. Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32). Blood Cells Mol Dis 2007; 39:366–368.PubMedGoogle Scholar
  125. 127.
    Corre J, Mahtouk K, Attal M et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21:1079–1088.PubMedGoogle Scholar
  126. 128.
    Iwamoto S, Mihara K, Downing JR et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007; 117:1049–1057.PubMedGoogle Scholar
  127. 129.
    Menendez P, Catalina P, Rodriguez R et al. Bone marrow mesenchymal stem cells from infants with MLL-AF4??acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 2009; 206:3131–3141.PubMedGoogle Scholar
  128. 130.
    Jager M, Schultheis A, Westhoff B et al. Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96). Anticancer Res 2005; 25:947–954.PubMedGoogle Scholar
  129. 131.
    Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14:2519–2526.PubMedGoogle Scholar
  130. 132.
    Christensen R, Alsner J, Sorensen F et al. Transformation of human mesenchymal stem cells in radiation carcinogenesis: long-term effect of ionizing radiation. Regen Med 2008; 3:849–861.PubMedGoogle Scholar
  131. 133.
    Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65:3307–3318.PubMedGoogle Scholar
  132. 134.
    Khakoo AY, Pati S, Anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 2006; 203:1235–1247.PubMedGoogle Scholar
  133. 135.
    Lu YR, Yuan Y, Wang XJ et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2007:7.Google Scholar
  134. 136.
    Qiao L, Xu Z, Zhao T et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008; 18:500–507.PubMedGoogle Scholar
  135. 137.
    Bexell D, Scheding S, Bengzon J. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 2010.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • René Rodríguez
    • 1
    Email author
  • Javier García-Castro
    • 2
  • Cesar Trigueros
    • 3
  • Mariano García Arranz
    • 4
  • Pablo Menéndez
    • 1
  1. 1.Andalusian Stem Cell Bank, Centro de Investigación BiomédicaConsejería de Salud-Universidad de GranadaGranadaSpain
  2. 2.Centro Nacional de Microbiología, Área de Biología Celular y del DesarrolloInstituto de Salud Carlos IIIMadridSpain
  3. 3.Mesenchymal Stem Cell DepartmentFundación InbiomedSan SebastiánSpain
  4. 4.Cell Therapy UnitLa Paz University Hospital-IdiPAZMadridSpain

Personalised recommendations